Chronic Hepatitis C Infection

Infectious Diseases
15
Pipeline Programs
5
Companies
27
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
5
0
8
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 12 programs with unclassified modality

On Market (1)

Approved therapies currently available

GS
EPCLUSAApproved
velpatasvir and sofosbuvir
Gilead Sciences
Hepatitis C Virus NS5A Inhibitor [EPC]oral2021

Competitive Landscape

5 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
1 program
1
1
EPCLUSA(SOF)Phase 21 trial
Active Trials
NCT01260350Completed292Est. Dec 2013
AbbVie
AbbVieNORTH CHICAGO, IL
9 programs
2
7
ABT-450/r/ABT-267, ABT-333Phase 3
ABT-450/r/ABT-267, ABT-333Phase 31 trial
ABT-450/r/ABT-267, ABT-333Phase 3
ABT-450/r/ABT-267, ABT-333Phase 31 trial
ABT-450/r/ABT-267, ABT-333Phase 31 trial
+4 more programs
Active Trials
NCT02476617Completed25Est. Dec 2016
NCT01782495Completed129Est. Jul 2017
NCT01833533Completed305Est. Sep 2014
+8 more trials
Abbott
AbbottABBOTT PARK, IL
2 programs
1
1
ABT-450/r/ABT-267, ABT-333Phase 31 trial
ABT-267Phase 21 trial
Active Trials
NCT01563536Completed12Est. Jun 2013
NCT01715415Completed395Est. Oct 2014
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
pegylated interferon and ribavirinPhase 21 trial
Active Trials
NCT01055821CompletedEst. Aug 2013
M&
Merck & Co.RAHWAY, NJ
2 programs
1
IDX719Phase 13 trials
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C PatientsN/A1 trial
Active Trials
NCT02065999Completed100Est. Jun 2022
NCT01919125Completed36Est. Feb 2014
NCT01813552Completed24Est. Mar 2013
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
AbbVieOmbitasvir/Paritaprevir/Ritonavir
AbbVieOmbitasvir/Paritaprevir/Ritonavir
AbbVieOmbitasvir/Paritaprevir/Ritonavir
AbbVieOmbitasvir/Paritaprevir/Ritonavir
AbbVieABT-450
AbbVieOmbitasvir/Paritaprevir/Ritonavir
AbbVieombitasvir/paritaprevir/ritonavir and dasabuvir
AbbVieOmbitasvir/Paritaprevir/Ritonavir
AbbVieOmbitasvir/Paritaprevir/Ritonavir
AbbVieOmbitasvir/Paritaprevir/Ritonavir
AbbVieOmbitasvir/Paritaprevir/Ritonavir
AbbVieABT-450/r/ABT-267, ABT-333
AbbVieABT-450/r/ABT-267, ABT-333
AbbVieABT-450/r/ABT-267, ABT-333
AbbottABT-450/r/ABT-267, ABT-333

Showing 15 of 27 trials with date data

Clinical Trials (27)

Total enrollment: 3,237 patients across 27 trials

NCT02582632AbbVieOmbitasvir/Paritaprevir/Ritonavir

A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults

Start: Nov 2015Est. completion: Dec 2016166 patients
Phase 3Completed
NCT02609659AbbVieOmbitasvir/Paritaprevir/Ritonavir

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection

Start: Oct 2015Est. completion: Dec 2016105 patients
Phase 3Completed
NCT02487199AbbVieOmbitasvir/Paritaprevir/Ritonavir

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease

Start: Sep 2015Est. completion: Dec 201618 patients
Phase 3Completed
NCT02504099AbbVieOmbitasvir/Paritaprevir/Ritonavir

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

Start: Jul 2015Est. completion: Dec 20163 patients
Phase 3Terminated
NCT02476617AbbVieABT-450

Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults

Start: Jun 2015Est. completion: Dec 201625 patients
Phase 3Completed
NCT02442284AbbVieOmbitasvir/Paritaprevir/Ritonavir

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection

Start: May 2015Est. completion: Oct 201699 patients
Phase 3Completed
NCT02442271AbbVieombitasvir/paritaprevir/ritonavir and dasabuvir

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil

Start: Apr 2015Est. completion: Sep 2016222 patients
Phase 3Completed
NCT02399345AbbVieOmbitasvir/Paritaprevir/Ritonavir

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults

Start: Mar 2015Est. completion: Nov 201510 patients
Phase 3Completed
NCT02219477AbbVieOmbitasvir/Paritaprevir/Ritonavir

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis

Start: Nov 2014Est. completion: Mar 201736 patients
Phase 3Completed
NCT02219503AbbVieOmbitasvir/Paritaprevir/Ritonavir

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

Start: Sep 2014Est. completion: Sep 201560 patients
Phase 3Completed
NCT02216422AbbVieOmbitasvir/Paritaprevir/Ritonavir

A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection

Start: Sep 2014Est. completion: Dec 201536 patients
Phase 3Completed
NCT01854528AbbVieABT-450/r/ABT-267, ABT-333

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults

Start: Jun 2013Est. completion: Jul 2015148 patients
Phase 3Completed
NCT01854697AbbVieABT-450/r/ABT-267, ABT-333

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

Start: Mar 2013Est. completion: Jul 2015311 patients
Phase 3Completed
NCT01833533AbbVieABT-450/r/ABT-267, ABT-333

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

Start: Mar 2013Est. completion: Sep 2014305 patients
Phase 3Completed
NCT01715415AbbottABT-450/r/ABT-267, ABT-333

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Start: Nov 2012Est. completion: Oct 2014395 patients
Phase 3Completed
NCT02486406AbbVieOmbitasvir/Paritaprevir/Ritonavir

A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

Start: Oct 2015Est. completion: Nov 202064 patients
Phase 2/3Completed
NCT02356562AbbVieOmbitasvir/Paritaprevir/Ritonavir

A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection

Start: Feb 2015Est. completion: Jul 201729 patients
Phase 2Completed
NCT01782495AbbVieombitasvir/paritaprevir/ritonavir and dasabuvir

A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients

Start: Feb 2013Est. completion: Jul 2017129 patients
Phase 2Completed
NCT01563536AbbottABT-267

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

Start: Feb 2012Est. completion: Jun 201312 patients
Phase 2Completed
NCT01260350Gilead SciencesSOF

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Start: Dec 2010Est. completion: Dec 2013292 patients
Phase 2Completed
NCT01055821Transgenepegylated interferon and ribavirin

Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients

Start: May 2010Est. completion: Aug 2013
Phase 2Completed
NCT01919125Merck & Co.IDX719

Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)

Start: Aug 2013Est. completion: Feb 201436 patients
Phase 1Completed
NCT01813552Merck & Co.IDX719

To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)

Start: Feb 2013Est. completion: Mar 201324 patients
Phase 1Completed
NCT01813513Merck & Co.IDX719

Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)

Start: Jan 2013Est. completion: Jul 201342 patients
Phase 1Completed
NCT02803138AbbVieOmbitasvir/Paritaprevir/Ritonavir

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C

Start: Jul 2016Est. completion: Oct 2018256 patients
N/ACompleted
NCT02581163AbbVieOmbitasvir/Paritaprevir/Ritonavir

Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium

Start: Oct 2015Est. completion: Feb 2018314 patients
N/ACompleted
NCT02065999Merck & Co.Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients

Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients

Start: Nov 2012Est. completion: Jun 2022100 patients
N/ACompleted

Related Jobs in Infectious Diseases

Senior Associate Scientist (contract), Upstream Polysaccharide Process Development

VaxCyte
San Carlos, California, United States
6h ago
$56/hr

Senior Associate Scientist (contract), Polysaccharide Analytical Development

VaxCyte
San Carlos, California, United States
6h ago
$56/hr

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
10h ago
$179K - $237K/yr

First Line Sales Leader (Medan)

GSK
Indonesia - Sumatera Utara
23h ago

General Worker

GSK
Pakistan - Sindh - Karachi
23h ago

Vaccine Business Manager (Jakarta)

GSK
Indonesia - DKI Jakarta
23h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)